The contraceptive called Vasalgel provided effective birth control in rhesus monkey groups for more than one year, according to researchers from California National Primate Research Center in the US.
With proof of efficacy in monkeys and rabbits, preparations are being made for the first clinical trial in humans, researchers said.
Male contraceptive options have not changed in over a century, and are currently limited to condoms and withdrawal (with high pregnancy rates in typical use), or vasectomy (meant to be permanent), they said.
"Vasalgel is a high molecular weight polymer that consists of styrene-alt-maleic acid (SMA) dissolved in dimethyl sulfoxide and could be the first long-acting, non-hormonal, potentially reversible male contraceptive to reach market," the company behind the gel said.
The polymer forms a hydrogel after injection into the vas deferens, creating a blockage to the passage of sperm.
It is thought that fluids are able to pass slowly through the gel, reducing back-pressure on the epididymis (the sperm storage area) that has been noted after vasectomy.
The purpose of the current study was to put Vasalgel to the ultimate test - preventing pregnancy, not just eliminating sperm - in larger animals more anatomically similar to humans, before human use. However, the contraceptive had benefits to the monkeys as well, they said.
Sixteen adult male rhesus monkeys received intravas injections of Vasalgel. After a one-week recovery, each male was returned to outdoor group housing, which included three to nine intact, breeding females with a successful reproductive history.
All males were monitored for at least one breeding season; 7 of the 16 were almost continually housed with females for two years.
The researchers reported that there were no conceptions after Vasalgel injections.
Complications were minor and included one incident of incorrect placement of Vasalgel into the vas deferens and the development of a sperm granuloma in one animal.
"While vasectomy is a quick and relatively simple procedure in humans, in monkeys there can be additional complications, as it is inherently more complex," said Angela Colagross-Schouten, lead veterinarian on the project.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
